Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy

This study aimed to clarify the real-world efficacy of sequential nivolumab for treating metastatic renal cancer after first-line molecular targeting therapy. Patients were divided into two groups (2014–2016 and 2017–2020) according to the year when they started primary treatment with molecular targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Obinata, Daisuke, Funakoshi, Daigo, Sakurai, Fuminori, Yoshizawa, Tsuyoshi, Mochida, Junichi, Yamaguchi, Kenya, Takahashi, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371577/
https://www.ncbi.nlm.nih.gov/pubmed/35960101
http://dx.doi.org/10.1097/MD.0000000000029510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371577/
https://www.ncbi.nlm.nih.gov/pubmed/35960101
http://dx.doi.org/10.1097/MD.0000000000029510

Ejemplares similares